Elisabeth Brouwer

List of Publications by Year
in descending order

195	12,283	44444 50	33145 104
papers	citations	h-index	g-index

196	196	196	14484
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Management of immune checkpoint inhibitor-induced polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2022, 81, e263-e263.	0.5	10
2	Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2022, 81, e210-e210.	0.5	13
3	Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. Rheumatology, 2022, 61, 1072-1082.	0.9	29
4	Ageing enhances cellular immunity to myeloperoxidase and experimental anti-myeloperoxidase glomerulonephritis. Rheumatology, 2022, 61, 2132-2143.	0.9	6
5	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology, 2022, 61, 2915-2922.	0.9	24
6	Dr. Conway et al reply. Journal of Rheumatology, 2022, 49, 120.2-121.	1.0	0
7	Comment on: Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis: reply. Rheumatology, 2022, 61, e185-e187.	0.9	1
8	Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open, 2022, 8, e001652.	1.8	6
9	Letter to the editor: Prevalence of connective tissue disease autoantibodies in a large longitudinal population-based cohort from the Netherlands. Autoimmunity Reviews, 2022, 21, 103063.	2.5	0
10	Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. Arthritis Research and Therapy, 2022, 24, 65.	1.6	8
11	Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 653-661.	0.5	49
12	Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8+ T cells in giant cell arteritis. Rheumatology, 2022, 62, 417-427.	0.9	8
13	Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. Seminars in Arthritis and Rheumatism, 2022, 55, 152017.	1.6	32
14	Comment on: Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway. Rheumatology Advances in Practice, 2022, 6, .	0.3	1
15	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. Journal of Rheumatology, 2021, 48, 1053-1059.	1.0	22
16	Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines). Rheumatology, 2021, 60, 658-666.	0.9	7
17	Pulmonary artery activity in Takayasuâ€™s arteritis, a role for [18F]FDG PET/CT?. European Heart Journal Cardiovascular Imaging, 2021, 22, 551-552.	0.5	0
18	Aortic involvement in giant cell arteritis. Joint Bone Spine, 2021, 88, 105045.	0.8	6

#	Article	IF	Citations
19	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatology, The, 2021, 3, e71-e82.	2.2	18
20	CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?. Frontiers in Immunology, 2021, 12, 654109.	2.2	6
21	A Review on the Value of Imaging in Differentiating between Large Vessel Vasculitis and Atherosclerosis. Journal of Personalized Medicine, 2021, 11, 236.	1.1	18
22	Effect of Anti-Rheumatic Treatment on the Periodontal Condition of Rheumatoid Arthritis Patients. International Journal of Environmental Research and Public Health, 2021, 18, 2529.	1.2	12
23	Therapy response evaluation in large-vessel vasculitis: a new role for [18F]FDG-PET/CT?. Rheumatology, 2021, 60, 3494-3495.	0.9	6
24	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatology, The, 2021, 3, e328-e336.	2.2	52
25	A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKLâ€40/Interleukinâ€13 Receptor Î±2 Axis. Arthritis and Rheumatology, 2021, 73, 2327-2337.	2.9	27
26	CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis. Frontiers in Immunology, 2021, 12, 686273.	2.2	15
27	Vasculitis therapy refines vasculitis mechanistic classification. Autoimmunity Reviews, 2021, 20, 102829.	2.5	13
28	Encouraging data on rituximab in polymyalgia rheumatica. Lancet Rheumatology, The, 2021, , .	2.2	1
29	Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica. Journal of Autoimmunity, 2021, 123, 102684.	3.0	20
30	Dr. Conway et al reply. Journal of Rheumatology, 2021, , jrheum.210913.	1.0	2
31	Distribution of monocytes subpopulations in the peripheral blood from patients with BehÃ§et's disease - Impact of disease status and colchicine use. Clinical Immunology, 2021, 231, 108854.	1.4	6
32	Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints. Annals of the Rheumatic Diseases, 2021, 80, 668-669.	0.5	6
33	Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. Journal of Clinical Medicine, 2021, 10, 4958.	1.0	15
34	Toward Reliable Uptake Metrics in Large Vessel Vasculitis Studies. Diagnostics, 2021, 11, 1986.	1.3	5
35	PET imaging in vasculitis. , 2021, , .		0
36	Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in Giant Cell Arteritis. Rheumatology, 2021, , .	0.9	10

#	Article	IF	Citations
37	Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort. Lupus Science and Medicine, 2021, 8, e000555.	1.1	3
38	High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. Rheumatology, 2020, 59, 176-184.	0.9	13
39	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.5	667
40	Effect of age and sex on immune checkpoint expression and kinetics in human T cells. Immunity and Ageing, 2020, 17, 32.	1.8	8
41	Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis. JAMA Internal Medicine, 2020, 180, 1295.	2.6	76
42	Distinct macrophage phenotypes skewed by local granulocyte macrophage colonyâ€stimulating factor (GMâ€CSF) and macrophage colonyâ€stimulating factor (Mâ€CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. Clinical and Translational Immunology, 2020, 9, e1164.	1.7	39
43	ANCA-associated vasculitis. Nature Reviews Disease Primers, 2020, 6, 71.	18.1	443
44	Levels of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor, Including IgA Isotypes, and Articular Manifestations in Ulcerative Colitis and Crohnâ€™s Disease. International Journal of Environmental Research and Public Health, 2020, 17, 8054.	1.2	7
45	Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 616-623.	1.6	40
46	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	0.9	56
47	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	0.9	128
48	What can negative temporal artery biopsies tell us?. Rheumatology, 2020, 59, 925-927.	0.9	8
49	Diagnostic value of axillary artery ultrasound in patients with suspected giant cell arteritis. Rheumatology, 2020, 59, 3676-3684.	0.9	26
50	The value of inquiring about functional impairments for early identification of inflammatory arthritis: a large cross-sectional derivation and validation study from the Netherlands. BMJ Open, 2020, 10, e040148.	0.8	1
51	Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA. Frontiers in Immunology, 2019, 10, 1638.	2.2	23
52	351.â€ƒEFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL. Rheumatology, 2019, 58, .	0.9	0
53	Neutrophil myeloperoxidase harbors distinct site-specific peculiarities in its glycosylation. Journal of Biological Chemistry, 2019, 294, 20233-20245.	1.6	35
54	194.â€ƒDISTRIBUTION OF MACROPHAGE SUBSETS IN TEMPORAL ARTERY BIOPSIES OF PATIENTS WITH GIANT CELL ARTERITIS. Rheumatology, 2019, 58, .	0.9	0

#	Article	IF	Citations
55	O26â€ƒEffects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial. Rheumatology, 2019, 58, .	0.9	0
56	272â€ƒAcute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial. Rheumatology, 2019, 58, .	0.9	0
57	The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age. Immunity and Ageing, 2019, 16, 22.	1.8	17
58	Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. Frontiers in Immunology, 2019, 10, 1981.	2.2	40
59	Methotrexate in Giant Cell Arteritis Deserves a Second Chance â€" A High-dose Methotrexate Trial Is Needed. Journal of Rheumatology, 2019, 46, 453-454.	1.0	8
60	055.â€ƒHIGH SERUM ANGIOPOIETIN-2 LEVELS IDENTIFY LARGE VESSEL INFLAMMATION IN PATIENTS WITH POLYMYALGIA RHEUMATICA. Rheumatology, 2019, 58, .	0.9	0
61	Glucocorticoid Dosages and Acuteâ€Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis and Rheumatology, 2019, 71, 1329-1338.	2.9	74
62	Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis. PLoS ONE, 2019, 14, e0211895.	1.1	7
63	Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology, 2019, 58, 1383-1392.	0.9	43
64	Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis. Frontiers in Immunology, 2019, 10, 83.	2.2	45
65	FRI0275â€…HIGH ANGIOPOIETIN-2 LEVELS ASSOCIATE WITH ARTERIAL INFLAMMATION AND LONG-TERM GLUCOCORTICOID REQUIREMENT IN POLYMYALGIA RHEUMATICA. , 2019, , .		0
66	FRI0266â€…ABERRANT PD-1 AND VISTA EXPRESSION ON CD4+ TH-CELLS IN GIANT CELL ARTERITIS. , 2019, , .		0
67	FRI0381â€…TROUGH SERUM DRUG LEVELS AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS PATIENTS ON LONG-TERM TREATMENT WITH TNF-Î± INHIBITORS. , 2019, , .		0
68	OP0211â€…ULTRASONOGRAPHY CAN POTENTIALLY BE THE FIRST CHOICE OF IMAGING IN SUSPECTED EXTRA-CRANIAL GCA. , 2019, , .		2
69	THU0330â€…PREVALENCE OF RAYNAUDâ€™S PHENOMENONIN THE NORTHERN PARTS OF THE NETHERLANDS: AN EPIDEMIOLOGICAL STUDY OF THE LIFELINES COHORT. , 2019, , .		0
70	THU0329â€…RED FLAG SIGNS OF SYSTEMIC SCLEROSIS ARE PREVALENT IN SUBJECTS WITH RAYNAUDâ€™S PHENOMENONIN THE GENERAL POPULATION AND MAY BE A PROXY FOR LUNG INVOLVEMENT. , 2019, , .		0
71	SAT0232â€…DISTRIBUTION OF MACROPHAGE SUBSETS IN TEMPORAL ARTERY BIOPSIES OF PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .		0
72	SAT0228â€…LEUKOCYTE DYNAMICS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA PATIENTS BEFORE, DURING AND AFTER TREATMENT. , 2019, , .		0

#	Article	IF	Citations
73	Mechanisms of Naive CD4+ T Cell Maintenance in the Elderly and Its Implications for Autoimmunity. , 2019, , 1573-1595.		0
74	Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?. Arthritis and Rheumatology, 2018, 70, 1366-1376.	2.9	54
75	Validation of the ACR-EULAR criteria for primary SjÃ¶grenâ€™s syndrome in a Dutch prospective diagnostic cohort. Rheumatology, 2018, 57, 818-825.	0.9	27
76	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Annals of the Rheumatic Diseases, 2018, 77, 636-643.	0.5	753
77	Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: Current status and future prospects. Autoimmunity Reviews, 2018, 17, 715-726.	2.5	53
78	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 925-933.	2.0	8
79	Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries. Annals of the Rheumatic Diseases, 2018, 77, e16-e16.	0.5	11
80	Towards precision medicine in ANCA-associated vasculitis. Rheumatology, 2018, 57, 1332-1339.	0.9	23
81	Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli etÂal. Arthritis Care and Research, 2018, 70, 1275-1275.	1.5	5
82	A Secreted Bacterial Peptidylarginine Deiminase Can Neutralize Human Innate Immune Defenses. MBio, 2018, 9, .	1.8	55
83	Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-Î± inhibitors. PLoS ONE, 2018, 13, e0196281.	1.1	11
84	Checks and Balances in Autoimmune Vasculitis. Frontiers in Immunology, 2018, 9, 315.	2.2	31
85	Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells. Frontiers in Immunology, 2018, 9, 1400.	2.2	13
86	Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells. Frontiers in Immunology, 2018, 9, 752.	2.2	24
87	Mechanisms of Naive CD4+ T Cell Maintenance in the Elderly and Its Implications for Autoimmunity. , 2018, , 1-23.		0
88	Detailed Analysis of the Articular Domain in Patients with Primary SjÃ¶gren Syndrome. Journal of Rheumatology, 2017, 44, 292-296.	1.0	11
89	Argonaute 2 immunoprecipitation revealed large tumor suppressor kinase 1 as a novel proapoptotic target of miRâ€21 in T cells. FEBS Journal, 2017, 284, 555-567.	2.2	7
90	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Annals of the Rheumatic Diseases, 2017, 76, 1184-1190.	0.5	73

#	Article	IF	Citations
91	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 491-496.	0.5	209
92	Autoantibodies against citrullinated histone H3 in rheumatoid arthritis and periodontitis patients. Journal of Clinical Periodontology, 2017, 44, 577-584.	2.3	35
93	Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis. Arthritis Research and Therapy, 2017, 19, 77.	1.6	18
94	Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor-Î± Blocking Therapy in Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2017, 44, 587-593.	1.0	11
95	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	2.6	78
96	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nature Reviews Rheumatology, 2017, 13, 578-592.	3.5	161
97	Trial of Tocilizumab in Giant-Cell Arteritis. New England Journal of Medicine, 2017, 377, 317-328.	13.9	974
98	Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gammadelta T-cells. Scientific Reports, 2017, 7, 5509.	1.6	44
99	Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis. Scientific Reports, 2017, 7, 6553.	1.6	45
100	Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?. Autoimmunity Reviews, 2017, 16, 1071-1078.	2.5	54
101	Changes in peripheral immune cell numbers and functions in octogenarian walkers â€“ an acute exercise study. Immunity and Ageing, 2017, 14, 5.	1.8	15
102	Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF-Î± inhibitors: Facet joints vs. vertebral bodies. Seminars in Arthritis and Rheumatism, 2017, 46, 562-568.	1.6	22
103	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Seminars in Arthritis and Rheumatism, 2017, 46, 657-664.	1.6	62
104	Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis. Arthritis Care and Research, 2017, 69, 694-702.	1.5	36
105	Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors. Arthritis Care and Research, 2017, 69, 1011-1019.	1.5	77
106	Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis. Frontiers in Immunology, 2017, 8, 1377.	2.2	8
107	Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-Î± inhibitors. PLoS ONE, 2017, 12, e0177231.	1.1	33
108	I88.â€ƒNOVEL THERAPEUTIC APPROACHES TO LARGE VESSEL VASCULITIS. Rheumatology, 2017, 56, .	0.9	0

#	Article	IF	Citations
109	Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clinical and Experimental Rheumatology, 2017, 35, 61-68.	0.4	15
110	Physical fatigue characterises patient experience of primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 255-261.	0.4	8
111	Regulatory CD4+ T-Cell Subsets and Anti-Citrullinated Protein Antibody Repertoire: Potential Biomarkers for Arthritis Development in Seropositive Arthralgia Patients?. PLoS ONE, 2016, 11, e0162101.	1.1	16
112	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Openâ€Łabel Randomized Controlled Trial. Arthritis and Rheumatology, 2016, 68, 1810-1817.	2.9	70
113	Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients. Scientific Reports, 2016, 6, 26021.	1.6	44
114	Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status. Journal of Rheumatology, 2016, 43, 1008-1016.	1.0	27
115	Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology, 2016, 55, 1143-1145.	0.9	63
116	Reduced levels of cytosolic DNA sensor AIM2 are associated with impaired cytokine responses in healthy elderly. Experimental Gerontology, 2016, 78, 39-46.	1.2	18
117	Age-determined severity of anti-myeloperoxidase autoantibody-mediated glomerulonephritis in mice. Nephrology Dialysis Transplantation, 2016, 32, gfw202.	0.4	10
118	Safety of treatments for primary SjÃ¶grenâ€™s syndrome. Expert Opinion on Drug Safety, 2016, 15, 513-524.	1.0	14
119	Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome. Journal of Rheumatology, 2016, 43, 383-387.	1.0	68
120	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. Journal of Rheumatology, 2016, 43, 182-186.	1.0	25
121	Aging-dependent decline of IL-10 producing B cells coincides with production of antinuclear antibodies but not rheumatoid factors. Experimental Gerontology, 2016, 75, 24-29.	1.2	22
122	Vessel involvement in giant cell arteritis: an imaging approach. Journal of Cardiovascular Surgery, 2016, 57, 127-36.	0.3	4
123	Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-Î± blocking therapy. Clinical and Experimental Rheumatology, 2016, 34, 191-9.	0.4	7
124	The peptidylarginine deiminase gene is a conserved feature of Porphyromonas gingivalis. Scientific Reports, 2015, 5, 13936.	1.6	49
125	Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 222.	1.6	21
126	Rheumatoid arthritisâ€“associated autoantibodies in nonâ€“rheumatoid arthritis patients with mucosal inflammation: a caseâ€“control study. Arthritis Research and Therapy, 2015, 17, 174.	1.6	59

#	Article	IF	Citations
127	Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH. Arthritis Research and Therapy, 2015, 17, 108.	1.6	14
128	Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF-Î± Blocking Therapy: A Prospective Longitudinal Observational Cohort Study. PLoS ONE, 2015, 10, e0122693.	1.1	46
129	Quantifying Distribution of Flow Cytometric TCR-VÎ² Usage with Economic Statistics. PLoS ONE, 2015, 10, e0125373.	1.1	39
130	Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Research and Therapy, 2015, 17, 134.	1.6	57
131	High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. Arthritis Research and Therapy, 2015, 17, 158.	1.6	10
132	Lowâ€affinity <scp>TCR</scp> engagement drives <scp>IL</scp>â€2â€dependent postâ€thymic maintenance of naive <scp>CD</scp>4+ T cells in aged humans. Aging Cell, 2015, 14, 744-753.	3.0	43
133	Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis. Medicine (United States), 2015, 94, e1542.	0.4	93
134	SF Treg cells transcribing high levels of Bcl-2 and microRNA-21 demonstrate limited apoptosis in RA. Rheumatology, 2015, 54, 950-958.	0.9	29
135	A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. Annals of the Rheumatic Diseases, 2015, 74, e15-e15.	0.5	62
136	Male and female patients with axial spondyloarthritis experience disease activity, physical function and quality of life differently: results from the Groningen Leeuwarden Axial Spondyloarthritis cohort: Table 1. Rheumatology, 2015, 54, 1333-1335.	0.9	10
137	Commentary: Periodontitis and Rheumatoid Arthritis: What Do We Know?. Journal of Periodontology, 2015, 86, 1013-1019.	1.7	45
138	Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology, 2015, 54, 1397-1402.	0.9	83
139	Immunoâ€miRs: critical regulators of Tâ€cell development, function and ageing. Immunology, 2015, 144, 1-10.	2.0	141
140	Expression of Lectin-Like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0132436.	1.1	28
141	Age-Associated Differences in MiRNA Signatures Are Restricted to CD45RO Negative T Cells and Are Associated with Changes in the Cellular Composition, Activation and Cellular Ageing. PLoS ONE, 2015, 10, e0137556.	1.1	23
142	T-cell Activation Induces Dynamic Changes in miRNA Expression Patterns in CD4 and CD8 T-cell Subsets. MicroRNA (Shariqah, United Arab Emirates), 2015, 4, 117-122.	0.6	37
143	Patient-tailored dose reduction of TNF-Î± blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clinical and Experimental Rheumatology, 2015, 33, 174-80.	0.4	20
144	Higher Bone Turnover Is Related to Spinal Radiographic Damage and Low Bone Mineral Density in Ankylosing Spondylitis Patients with Active Disease: A Cross-Sectional Analysis. PLoS ONE, 2014, 9, e99685.	1.1	25

#	Article	IF	Citations
145	P1. Giant cell arteritis: B cells revisited. Rheumatology, 2014, 53, i12-i12.	0.9	0
146	Clinical studies on bone-related outcome and the effect of TNF-Î± blocking therapy in ankylosing spondylitis. Current Opinion in Rheumatology, 2014, 26, 259-268.	2.0	18
147	Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. Genes and Immunity, 2014, 15, 115-125.	2.2	111
148	Aging disturbs the balance between effector and regulatory CD4+ T cells. Experimental Gerontology, 2014, 60, 190-196.	1.2	115
149	Abatacept treatment reduces disease activity in early primary SjÃ¶gren's syndrome (open-label proof of) Tj ETQq1 1 0.784314 rgBT /Ove	0.5	205
150	EULAR SjÃ¶gren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Annals of the Rheumatic Diseases, 2014, 73, 472-474.	0.5	34
151	A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, R108.	1.6	19
152	Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia Rheumatica. Arthritis and Rheumatology, 2014, 66, 1927-1938.	2.9	104
153	Antibodies againstPorphyromonas gingivalisin seropositive arthralgia patients do not predict development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1277-1279.	0.5	35
154	Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinical assessments. Arthritis Research and Therapy, 2013, 15, R99.	1.6	49
155	Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 769-775.	0.5	70
156	Lessons to be learned from periodontitis. Current Opinion in Rheumatology, 2013, 25, 241-247.	2.0	33
157	Improved early identification of arthritis: evaluating the efficacy of Early ArthritisRecognitionClinics. Annals of the Rheumatic Diseases, 2013, 72, 1295-1301.	0.5	32
158	Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. Annals of the Rheumatic Diseases, 2013, 72, 1302-1307.	0.5	17
159	Circulating CD4+CD161+ T Lymphocytes Are Increased in Seropositive Arthralgia Patients but Decreased in Patients with Newly Diagnosed Rheumatoid Arthritis. PLoS ONE, 2013, 8, e79370.	1.1	39
160	Validity and Reliability of the Dutch Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire. PLoS ONE, 2013, 8, e55912.	1.1	23
161	Dual Role of miR-21 in CD4+ T-Cells: Activation-Induced miR-21 Supports Survival of Memory T-Cells and Regulates CCR7 Expression in Naive T-Cells. PLoS ONE, 2013, 8, e76217.	1.1	61
162	Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Annals of the Rheumatic Diseases, 2012, 71, 180-185.	0.5	43

#	Article	IF	Citations
163	Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus, 2012, 21, 959-968.	0.8	43
164	Genetic variants inIL15associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Annals of the Rheumatic Diseases, 2012, 71, 1651-1657.	0.5	57
165	Baseline predictors of response to TNF-Î± blocking therapy in ankylosing spondylitis. Current Opinion in Rheumatology, 2012, 24, 290-298.	2.0	33
166	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2012, 71, 638-641.	0.5	354
167	Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nature Genetics, 2012, 44, 3-5.	9.4	44
168	Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary SjÃ¶gren's syndrome treated with rituximab. Annals of the Rheumatic Diseases, 2012, 71, 1297-1302.	0.5	99
169	Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Research and Therapy, 2012, 14, R222.	1.6	179
170	The effect of three years of TNF-alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Research and Therapy, 2012, 14, R98.	1.6	42
171	The periodontium of periodontitis patients contains citrullinated proteins which may play a role in <scp>ACPA</scp> (antiâ€citrullinated protein antibody) formation. Journal of Clinical Periodontology, 2012, 39, 599-607.	2.3	121
172	Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology, 2011, 50, 665-673.	0.9	35
173	Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Research and Therapy, 2011, 13, R94.	1.6	179
174	Rheumatoid arthritis and periodontitis; a possible link via citrullination. Anaerobe, 2011, 17, 196-200.	1.0	43
175	The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporosis International, 2011, 22, 1431-1439.	1.3	89
176	Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis. Journal of Rheumatology, 2011, 38, 1644-1650.	1.0	40
177	Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci. PLoS Genetics, 2011, 7, e1002004.	1.5	307
178	Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskeletal Disorders, 2010, 11, 61.	0.8	48
179	Effectiveness of rituximab treatment in primary SjÃ¶gren's syndrome: A randomized, doubleâ€blind, placeboâ€controlled trial. Arthritis and Rheumatism, 2010, 62, 960-968.	6.7	427
180	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics, 2010, 42, 508-514.	9.4	1,132

#	Article	IF	Citations
181	Lack of Association of C-C Chemokine Receptor 5 Î”32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity. Journal of Rheumatology, 2010, 37, 2226-2231.	1.0	16
182	Common and different genetic background for rheumatoid arthritis and coeliac disease. Human Molecular Genetics, 2009, 18, 4195-4203.	1.4	128
183	Role for CaMKII Inhibition in Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2009, 1173, 706-711.	1.8	15
184	Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Annals of the Rheumatic Diseases, 2009, 68, 1787-1788.	0.5	83
185	Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibodyâ€“associated systemic vasculitis: Antiâ€“proteinase 3â€“mediated neutrophil activation is independent of the role of CD177â€expressing neutrophils. Arthritis and Rheumatism, 2009, 60, 1548-1557.	6.7	82
186	Regulation of Cytokine-Induced HIF-1Â Expression in Rheumatoid Synovial Fibroblasts. Annals of the New York Academy of Sciences, 2007, 1108, 340-348.	1.8	92
187	Antimyeloperoxidase-associated Lung Disease. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 987-994.	2.5	48
188	Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney International, 1998, 53, 253-263.	2.6	89
189	Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. Clinical and Experimental Immunology, 1996, 105, 321-329.	1.1	28
190	Renal ischemia/reperfusion injury contributes to renal damage in experimental anti-myeloperoxidase-associated proliferative glomerulonephritis. Kidney International, 1995, 47, 1121-1129.	2.6	15
191	Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney International, 1994, 45, 1120-1131.	2.6	177
192	Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential. Kidney International, 1994, 46, 1-15.	2.6	366
193	Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model.. Journal of Experimental Medicine, 1993, 177, 905-914.	4.2	195
194	Induction of an Humoral and Cellular (Auto) Immune Response to Human and Rat Myeloperoxidase(MPO) in Brown-Norway(BN), Lewis and Wistar Kyoto(WKY) Rat Strains. Advances in Experimental Medicine and Biology, 1993, 336, 139-142.	0.8	7
195	Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. Frontiers in Medicine, 0, 9, .	1.2	13